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ABSTRACT
THE PROTECTIVE EFFECTS A FULL-TERM PREGNANCY PLAYS AGAINST
MAMMARY CARCINOMA
MAY 2010
MATTHEW P. CARTER, B.S., UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by: Professor Sallie Smith/Schneider PhD

Countless epidemiological studies have consistently shown that a full-term
pregnancy conveys a significant reduction in the lifetime risk of developing breast
cancer. We chose to study healthy breast tissue from parous and nulliparous women
undergoing reduction mammoplasty surgery. By doing high throughput microarray
analyses, we attempted to identify potential genes that are differentially regulated in
response to a full term pregnancy. The genes suggested by our microarray were diverse in
function. Many of our subsequent PCR assays were done on genes involved in DNA
damage response (DDR). More specifically, many genes encompassing the nucleotide
excision repair (NER) pathway were found to be significantly upregulated in the parous
breast, and could provide a mechanism conveying protection against breast cancer.
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CHAPTER 1
INTRODUCTION

Parity Induced Protection against Breast Cancer

Breast cancer remains the second leading cause of death among women despite
our advances in understanding and treating the disease. In 2007 alone, more than 178,000
new cases of breast cancer were diagnosed, and an estimated 40,460 additional deaths are
believed to result from these diagnoses (Jemal et. al 2009). Epidemiological studies have
identified many different factors which pose both a positive and negative risk against
breast cancer. Such factors include age, geographic location, socioeconomic status,
familial history of breast cancer, mammographic density, history of benign breast disease,
ionizing radiation, bone density, height, IGF-1 and prolactin levels, and chemopreventive
agents (Dumitrescu et. al 2005). Countless epidemiological studies have also consistently
shown that a full-term pregnancy conveys a significant reduction in the lifetime risk of
developing breast cancer regardless of many of these aforementioned risk factors. It was
first reported that women who underwent a full-term pregnancy before the age of 20
enjoy half the risk of developing breast cancer over the course of their life when
compared to nulliparous women (Macmahon 1970). Conversely, parity has also been
reported to simultaneously increase the short-term risk of developing cancer immediately
following childbirth (Lambe et al 1994). This long-term parity protective effect is a
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powerful observation, and it is a phenotype that must be conveyed molecularly. This
project was aimed at further elucidating this molecular basis.
Microarray analyses of laser-dissected epithelium from parous women have
produced a transcriptomic signature corresponding with a deregulated expression of an
eclectic panel of genes involved in DNA damage repair, programmed cell death, immune
surveillance, and growth regulation to name a few (Russo et al 2006). Although many of
these studies have been instrumental to further identifying the genetic basis of this
reduced risk, they neglect any genes not directly found in the epithelial portion of
mammary tissue. The human breast is comprised of, and stratified by several different
types of tissue: a dense stromal layer that encircles the epithelium, and a diffuse adipose
fraction that further surrounds the stroma. Our study is important in this respect, because
our fingerprint should be more encompassing of any of the important players within and
beyond the epithelial component of the mammary gland. Further identification of this
parity-induced fingerprint in the mammary gland is indispensable as it will further
elucidate the mechanisms by which early parous women are much less likely to develop
breast cancer over their lifetime. Ultimately, this identification could serve as the basis
for developing new target-based chemotherapeutic therapies.

Rodent Models and Their Signficance as a Model

Rodent models have proven indispensible to elucidating the basis of the
protection conveyed by a full-term pregnancy. The first important transformation of the
rodent mammary gland occurs during maturation. Cap cells are a population of basal-like
epithelial cells responsible for the ductal outgrowths seen during maturation of the
2

mammary glands. These cap cells are found distally in the lobules, at the apex of the
duct. Cap cells in this apical region are multipotent as they progressively alter in
morphology and gradually transform into a mature myoepithelial species. Cap cells
eventually infiltrate the stroma, this becomes one of the termination cues for ductal
elongation that occurs during puberty (Williams et al 1983). Cap cells can therefore be
defined as a stem cell population that serves as a reservoir from which new basal and
myoepithelial cells can arise during ductal morphogenesis and elongation (Williams et al.
1982).
The second radical transformation of the rodent mammary gland occurs during
pregnancy. During gestation, there is a robust period of proliferation and differentiation
and maximal growth occurs at parturition when the gland is ready for lactation. In rodent
models, this change in architecture in the mammary gland has been shown to be
somewhat permanent and can be appreciated even after 21 days of lactation, and 28 days
of postlactational
involution
(Figure 1.1). It
was
demonstrated
that a full-term

Figure 1.1 - Carmine stained mammary glands from Sprague
Dawley Rats and two different strains of mice. Glands represent
ductal architecture after 28 days of post-lactational involution
evidencing that the architectural changes are permanent. D’cruz
et al 2008

pregnancy in
Sprague Dawley rats causes a shift in the cell-cycle profile and ultimately leads to
differentiation in the mammary gland and thereby prevents the initiation of cancer (Russo
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et. al 1980). We also know that the same protective effect can be conveyed chemically by
treating virgin rats with the placental hormone Human Chorionic Gonadotropin (hCG) as
well as the ovarian hormones Estrogen and Progesterone (E&P) (Russo et. al 1990,
Swanson et. al 1997). We know that hCG (a pregnancy hormone) protects the mammary
gland against chemically-induced carcinogenesis where upon binding it’s receptor it
causes transcription of a vast panel of genes which act to differentiate the mammary
epithelium. More specifically, hCG induces the synthesis of Inhibin A and Inhibin B
mRNAs, and hCG causes the downregulation of Estrogen Receptor alpha (ERa) by
methylation of CpG islands (Srivastava et. al 1999, and Russo et. al 2007). It was shown
that mice with a complete deletion in the βB subunit have severely depleted ductal
outgrowths during pregnancy, and can never effectively lactate after birth (Robinson and
Hennighausen, 1997).
This persistent change in the ductal architecture is also accompanied by a
radically different transcriptional fingerprint that lasts over the life of the animal (D’cruz
et al 2008). A total of 14 genes with a diverse set of functions (eg. Growth factors, cell
metabolism enzymes, immune factors, and cell adhesion molecules, etc), were found to
be differentially regulated in response to parity. These same genes could be used as
predictors to blindly discern between parous and nulliparous animals of the same age
(D’cruz et. al 2008).
Although rodent studies have been instrumental in identifying the molecular
players and dissecting the pathways conveying this parity protective effect, human
mammary tissue is the most relevant system to study as it directly relates to human breast
cancer. With this in mind, it is tremendously difficult to find specimens of human
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mammary tissue that all fit into a specific paradigm because these populations of women
tend to have significant variations in reproductive history, as well unique lifestyles and
environments (J. Russo et al 1988). Although this reproductive history could be fairly
accurately assessed by the information from our post-operative interview, many other
factors such as race, ethnicity, diet, BMI, point of estrous, etc., could act as confounding
variables.

Experimental approaches to identifying signatures

Our first approach to identifying molecular players was done by studying normal
snap-frozen mammary tissue from reduction mammoplasties. By convention, we called
these reduction tissues time 0 (T=0) based on the fact they represent the tissues without
any experimental treatment. Patient mammary tissue was selected, age matched, and
RNA was isolated from these specimens and a sent for microarray analysis. A heatmap
was created showing genes that were differentially regulated in response to parity. In
order to validate data generated from our microarrays, RNA was re-isolated from the
same patients’ mammary tissue, cDNAs were created, and Quantitative Polymerase
Chain Reaction (QPCR) experiments were performed. In several cases, these
differentially regulated genes were assessed at the level of protein by IHC.
In our second approach, we hypothesized that we could identify molecular
pathways altered by a full-term pregnancy by comparing responses in gene expression of
mammary tissue from parous and nulliparous women in response to ionizing radiation.
For our experiments, we chose ionizing radiation (γIR) to perturb the explants because it
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is well-recognized as a potent carcinogen in the mammary gland that causes mutations by
directly causing double-stranded DNA breaks (DSBs). Ionizing radiation has also been
shown to indirectly affect cells by means of “bystander effects.” For example, selectively
irradiating a single human fibroblast causes cell damage to another 80-100 adjacent
unirradiated fibroblasts in vitro (Belyakov et. al 2001). Bystander effects are wellcharacterized by the exchange and rearrangement of chromosomes, as well mutations,
apoptosis, genomic instability (Morgan 2003). Bystander effects aren’t necessarily
detrimental to tissues and may actually serve as mechanism by which the stroma can
survey and protect the gland from excessive damage. It’s been reported that bystander
cells show a robust proliferative response while simultaneously secreting growth
inhibitory factors to adjacent tissues (Gerashchenko2005, Komarova 1998). γIR has been
crucial to this study because it allows us to expose mammary gland to an acute
carcinogenic event and examine the ways these tissues differentially respond to stress as
a function of the patient’s parity status. In addition to looking at the molecular players
affected by IR, we also wished to test if the parous mammary gland was more or less
sensitive to death by TUNEL assay.
This second approach differs from the first in the respect that we are observing
how the parous breast differentially responds to carcinogenic stress. Conversely, our first
approach represents a method to look at basal levels of transcripts that might be
differentially regulated in the parous breast.
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CHAPTER 2
PUTATIVE MOLECULAR PLAYERS CONVEYING THE PARITYPROTECTIVE EFFECT AGAINST BREAST CANCER

Introduction

Involvement of Growth Factors Affected By Parity
Intuitively, growth factors (both growth promoting and inhibitory) should be an
incredibly important family of genes affected by a full-term pregnancy as the mammary
gland is marked phenotypically by a radical outgrowth followed by a marked involution.
Members of and related to the Insulin-like Growth Factors (IGFs) have been shown to be
permanently deregulated in response to parity. Insulin-like Growth Factor 2 Receptor
IGF2R, Insulin-like growth factor binding protein 4 IGFBP4, and IGFBP7 have shown to
be persistently upregulated in the parous mammary gland (Russo 2005).
Transforming growth factor-beta (TGF-β) is a multifunctional family of cytokines
that regulates tissue development as well as repair processes. Many different members of
and related to this family have been identified as possible players conveying this parityprotective effect in humans as well as rodents. Latent transforming growth factor β
binding protein 4 (LTBP4) was shown to be significantly upregulated in the parous breast
(Russo et al 2008). The ligand TGFβIII was shown to be upregulated in mammary gland
of parous rodents (D’cruz et al 2002). Type III TGF-β receptor (TβRIII) is
downregulated in a wide range of human cancers, including breast cancer. TβRIII is well
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supported in the literature as a bona fide tumor suppressor gene and when TβRIII
expression is restored in human breast cancer cells, breast tumor invasion, angiogenesis,
and metastasis are inhibited in vivo (Dong et. al 2007). Interestingly, the ligands TGFβ2
as well as inhibin bind this receptor and this could be one of the receptor-ligand
interactions by which inhibins mediate their growth-like effects on the mammary
epithelium.
Activins and inhibins are similar in structure to TGFβ and as such are classified as
members of the TGFβ superfamily. Activins and inhibins are also the most important
sub-families of growth factors to consider as they are so well-implicated in differentiation
as well as proliferation. Activins indirectly enhance the synthesis of follistatin in cultured
cells from the anterior pituitary (Bilezikjian et al 1993). Activins are also well implicated
molecularly in inducing apoptosis, immune responses, as well as wound repair (Chen et
al 2006, Sulyok et al 2004). Interestingly, activins and inhibins have opposing functions
of one another. Inhibins act to downregulate both the synthesis of and the secretion of
FSH from the pituitary (Ling et al 1987). Rodent studies have shown that mice treated
with DMBA develop mammary tumors at a very high rate. As mentioned previously, by
treating with the pregnancy hormone hCG, the rate of tumorigenesis is greatly reduced,
and there is a marked increase in the α and β inhibin subunits at the mRNA level as well
as the protein level in the human breast (Srivastra et al 1999). In addition, multiple
publications have demonstrated the prevalence of these growth factors in both normaladjacent and diseased human breast. Inhibin and activin α, βA, and βB subunits (both at
the message and protein level) were reported to be present in normal breast tissue
regardless time during menstrual cycle or menopause (Reis et al 2004). Interestingly,
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activins and inhibins might very well be the most important growth factors involving the
ductal outgrowths during pregnancy (Reis et al 2004). Additionally, activin A and its
endogenous binding protein follistatin are present in human milk during the first week of
lactation (Reis et al 2004). These families almost certainly have some bearing on
downstream targets that convey this parity-protective effect in the mammary gland.
Literature also suggests that members of the Notch family almost certainly play
some role in the transformation of the mammary gland during pregnancy. Notch is a type
I transmembrane receptor with multiple epidermal growth factor-like (EGF) repeats.
Notch is well-known for its ability to affect cell-fate decisions during development.
Estradiol-induced angiogenesis in MCF-7 breast cancer cells in a 3-D culture is
completely dependent on Notch signaling (Soares et al 2004). Notch is not only
implicated on benign developmental processes, but it also has been reported to play an
indispensable role in cancer though stem cell maintenance. For example, expression of
the constitutively active intracellular domains of Notch1 or Notch2 protects glioma stem
cells against radiation (Wang et al 2009). This molecule is indispensable for the crosstalk
seen between physically adjacent cells in multiple tissues, including the breast. As Notch
signaling serves as a means of surveying and maintaining a normal stem cell population
in the mammary gland, it has great potential to play roles in the protection induced by
pregnancy.

Immune Signatures Imparted By Parity
One of the criteria of a malignancy is that it must be impervious to the hosts’
immune system. If a malignant cell cannot evade the immune system, it would almost
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immediately be eliminated, and never progress to form advanced disease. It would seem
likely that molecular players involved in immune surveillance should have a generous
hand in protecting the early parous breast from cancer. Not surprisingly, several
important genes with important roles in the immune system have been reported to be
upregulated in the parous mammary gland.
Complement component (C3), plays an extremely important role in detection and
elimination of foreign bodies and potentially carcinogenic cell species. Activation of C3
plays a vital role to the three complement pathways in immunity and results in
inflammation and elimination of self and non-self targets (Bert et al 2005). C3 was
reported to be upregulated in the mammary gland of post-menopausal women. This gene
could represent a way to sensitize the immune system to surveillance and identification of
potentially carcinogenic cells. Genes such as granulysin are also upregulated in the
parous breast of post-menopausal women, and granule-mediated cytolysis by CTL and
NK cells (Balogh et al 2005, Pena et al 1997). Upregulation of granulysin represents a
way to exploit the lytic functions of immune cells and better sensitize the immune system
to prohibit the maturation and progression of cancer. Lastly, an important piece of the
immune system’s protection against cancer should come from a sensing through
chemotaxis. CCL5 and Interleukin 8 (IL8) were both found to be upregulated 11-fold and
76-fold in the parous breast, respectively (Russo et al 2007). CCL5 functions to attract T
helper cells to a site of infection. IL8 functions as a chemoattractant to neutrophils which
can then act to further recruit other leukocytes in order to destroy other pre-malignant or
malignant cells. Immune genes are a vital component of the progression of cancer and
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thus are essential to consider when hypothesizing about the protective signature induced
by pregnancy.
This project was aimed at further identifying and characterizing the permanent
molecular fingerprint imparted by parity in the human mammary gland. The literature
suggests that many of the genes that are significantly changed in response to parity are
genes involved in immune-surveillance, growth regulation, DNA repair, programmed cell
death, transcription, and chromatin structure/activators/co-activators (Balogh et al. 2006,
2007). This characterization is extremely important as it will provide a basis for
preventative measures as well as novel targets for the development of chemo-protective
agents against breast cancer.

Materials and Methods

Zero Time Human Mammary Tissue
Women undergoing elective reduction mammoplasties were asked to enroll in our
study and donate their excised tissue. Immediately following surgery, roughly 70 grams
of normal breast tissue was procured and dissected under sterile conditions. Tissue was
then minced, placed in cryogenic vials, and flash frozen in liquid nitrogen. Pieces of
tissues were also fixed in formalin. RNA was sent out for microarray analyses and
Quantitative PCR was performed to confirm our results.
Microarray Analyses
All microarrays were performed at the University of North Carolina at Chapel
Hill. Total RNA from Stratagene Universal Human Reference (spiked with 1:1000 with
MCF-7 RNA and 1:1000 with ME16C RNA to increase expression of breast cancer
11

genes) was amplified and labeled with Cy3 according to Agilent protocols as described in
Hu et al. (17). Total RNA from RM was labeled with Cy5. Agilent 4X44K arrays and
Agilent custom 244K arrays were used (with some reduction mammoplasty (RM), and
normal adjacent to cancer (CN) patients processed on each format). Only probes that
were present on both formats were utilized in the final analysis and intraclass correlation
coefficients for duplicate experiments conducted on the same platform (range from 0.xx –
0.xx) did not show meaningful differences from those conducted on different platforms
(range from 0.xx – 0.xx). Principal components analysis also suggested no substantial
difference between the two platforms. Duplicate microarrays corresponding to the same
patient sample were combined by averaging.
RT and QPCR
Total RNA from 50 mg of flash-frozen explants was isolated using TRIzol
reagent (Invitrogen) standard protocol. Libraries were generated with QSCRIPT (Quanta
Biosciences) using 100ng of total RNA as a template. Replicates were then diluted 1:10
for QPCR analysis. Ten independent RT reactions were pooled together to account for
RT variations, then serially diluted to generate a standard curve. Relative amounts
(Arbitrary units) of target genes and normalizer genes were determined by plotting the
critical threshold (ct) values on the standard curve.

Results

Our final microarray contained 64 loose gene signatures from over 600 genes that
were altered by parity (figure 2.1). These arrays contained genes that participate in many
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different biological functions. Examples of these functions include death, proliferation,
cellular stress, ubiquitin/proteosomal degradation, Wnt signaling, and translation to name
a few (figure 2.2). NR4A2 functions in cellular survival and was found to be upregulated
in the parous mammary gland. Conversely, many pro-death genes such as Bax, Caspase
8, and ApoL6 were downregulated in the parous breast. After generating this heatmap,
our next step was to verify some of these genes by QPCR. Changes in transcript from
genes such as apolipoprotein 6 (APOL6), protocadherin 1 (PCDH1), ATPase, class V,
type 10A (ATP10A), forkhead binding protein 1 (FKBP1), homeobox protein class 9
(HOXC9), and Caspase 8 were genes that were found to be insignificant when assayed by
QPCR.
Nuclear receptor subfamily 4, group A, member 2 (NR4A2 or Nurr1) was found to
be significantly upregulated in the parous breast (p=.027; figure 2.3). We then sectioned
and stained 6 parous and 6 nulliparous patients for Nurr1 based on the significant
difference seen at the transcriptional level. Nurr1 immunoreactivity was predominately
found in the ductal epithelium. There was strong NR4A2 immunoreactivity in the stroma,
and a signal was also seen in the adipose that was proximal to the ducts (Figure 2.4). No
significant difference in Nurr1 protein could be appreciated between parous and
nulliparous patient groups.
Clusterin (CLU) was also tested by QPCR because it was previously reported by
Russo to be differentially regulated in response to parity. Our attempts proved
unsuccessful as a set of reliable primers for either of the two CLU isoforms could not be
generated. Our next goal was to section and stain 6 parous and 6 nulliparous 0-time
reduction mammoplasty patients for CLU by IHC. Many tissues of the mammary gland
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stained intensely for CLU (figure 2.3). CLU stained intensely in the stroma surrounding
the ducts. In the epithelium, CLU seemed to stain intensely on the luminal border of the
ducts. There wasn’t any appreciable difference in CLU protein levels between parous and
nulliparous patients.

Discussion

There were several deregulated genes included in our heatmap that, based on the
literature should not be epithelial in origin. These genes are strongly suggestive that our
array represents additional tissues in addition to the epithelium. Examples of these genes
include macrophage expressed gene 1, (MPEG1), fibroblast growth factor 1 (FGF1), and
fatty acid desaturases (FAD1&2). These genes are representative of immune cells, stroma
and adipose tissues, respectively. Accordingly, we can be fairly confident that our array is
representative of whole mammary tissue as opposed to just the epithelial component of
the mammary gland.
Almost all of the genes chosen for QPCR verification were determined to be
statistically insignificant. This is an important in itself because the statistical models had
to be greatly relaxed in order to generate our parity-induced heatmap. Ultimately, our
microarray data served as a hypothesis-generating model as to what genes may be
conveying the parity-protective effect against breast cancer. The insignificance that we
saw is also indicative that microarray analysis of whole human breast tissue may not be
the most appropriate scientific method to study transcript levels. Interestingly, several
genes such as ATP10A and HOXC9 did verify the same trends as the heatmap with an
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increase in transcript abundance with parity. Although the trends demonstrated by QPCR
and our heatmap agreed, neither of these genes reached significance.
Of the many different genes we chose for verification, only one was determined to
be statistically significant. NR4A2 was suggested by our microarray, and was confirmed
to be significantly upregulated in the parous breast. NR4A2 is an important gene for
supporting pro-survival of breast cancer cells, and knockdown of NR4A2 leads to an
increased rate of anoikis in anchorage independent conditions (Ke et al 2004). Likewise,
the upregulation of NR4A2 in the parous breast could be a means by which we could
describe a decreased sensitivity to death. NR4A2 or Nurr1 has also been identified as a
transcription factor that drives interleukin 8 (IL8) expression. If cells are co-treated with
the ligand TNF-α, it causes the secretion of IL8 protein (Aherne et al 2009). Vascular
endothelial cells express both types of IL-8 receptors which play a role in regulating
tumor and VEC activation which controls proliferation, angiogenesis and metastasis in
breast cancer (Miller et al. 1998). As previously mentioned, an increased immune
surveillance partially through the chemoattractant IL8 is a mechanism by which the
parous breast can identify and eliminate the early stages of tumorigenesis by recruiting
immune cells to the site of the lesion. We had hoped to see a similar induction of Nurr1 at
the level of protein by way of IHC. We stained 6 age-matched parous and nulliparous
patients and did not see any appreciable difference in Nurr1. There didn’t seem to be any
difference of this protein based on the age of the patient as well.
Clusterin (CLU) was of interest on our heatmap because it has been reported
previously to be persistently upregulated in response to parity (Russo et al 2006).
Interestingly there are two different splice variants of CLU that seem to have different
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roles. Each one of these transcriptional isoforms differs in their 5’ UTR, however only
one of these isoforms is translated into a mature form. Intuitively, if CLU is upregulated
in the protected parous gland it would seem it should function as a tumor suppressor
gene. The literature tells a different story. CLU has been reported as a viable biomarker
for stage III ovarian adenocarcinoma, as well as endometrial cancer (Partheen et al 2008).
Although reports of CLU overexpression in cancer seem unexpected, the functions of this
protein have still yet to be correctly identified. We would expect the functions of CLU to
be diverse based on the diffuse staining patterns that were seen in our IHC study. CLU
has been reported to have functions in cell-cell interactions, apoptosis, protecting fluidtissue interactions from stress, transporting lipids just to name a few (Wilson et al 2000).
More exciting than this eclectic group of functions, is the number of different ligands that
can bind with this glycoprotein in a tissue-specific manner. CLU has been found
complexed to apolipoprotein A-I in human plasma, and Glutathione S transferase (GST)
as well as Complement components (eg C3) in cerebrospinal fluid (Ghizo et al 1990,
1993). CLU could possibly be acting to sequester and dispose of excess ligands in
metabolically overactive tumor environment, and is ultimately acting to reduce stress to
the surrounding tissues.
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18SrRNA
CK14
CK18

Forward
GGA GAG GGA GCC TGA GAA AC
TTC TCC TCT GGA TCG CAG TC
CAC AGT CTG CTG AGG TTG GA

RPS3

GCA AGA TGG CAG TGC AAA TA

ERCC2

GGC CTC CTG GTA TGA GCA

CASP8

TAG GGG ACT CGG AGA CTG C

SNIP1

GAG CCC GAG GAG TTA GCC

APOL6

AGT GAG GCT GGT GTT GGT TT

EN1
ATP10A

CAT GGC CCA GGG ACT GTA
GGA GGT CAT CAC CCT GAA TG

TGFBII

CCA AAG GGT ACA ATG CCA AC

CXCL9

CCT TAA ACA ATT TGC CCC AAG

TRIAD 3

TCC TCA GCA GCA TGA AGA AG

FADD
TNFRSF10c

CAG AGC CCA TGC TCA ACC
CCC TAA AGT TCG TCG TCG TC

NR4A2
TGFBRIII

TGA AGA GAG ACG CGG AGA AC
GAT TTC ATC TTC GGC TTG AAA

GPX2

GTC CTT GGC TTC CCT TGC

P53 AIP1
ARIIA
TK1

AGG GAG CAG GAG CTG GAT
AAA GCC CAG TTG CTT AAC GA
CGT CGA TGC CTA TGA CAG C

TRAF 5

TTC AAG CAG TTT GCA CAG TTG

TRAF 7
PCDH7

CCA GCA CCC TTG CCT ACT C
CTA CCA CCA GCC AAC ACA TTT

AICDA
HOXC9

GAC TTT GGT TAT CTT CGC AAT
AAG
GCA GCA AGC ACA AAG AGG A

FKBP1A
TGIF

CTC TAG GGG TTG CAC TCT GG
TGG GAT CAG AGC GTC CTG TT

Reverse
TCG GGA GTG GGT AAT TTG C
ATG ACC TTG GTG CGG ATT T
GAG CTG CTC CAT CTG TAG
GG
ACT CAT TCA GTT CAG CTT
TGA AGA
CCT GGG TCT CAA TAA AGA
GCA
TTT CTG CTG AAG TCC ATC
TTT TT
TCT TAC TGC GAG GAG ACT
TGC
CGT CTT GTA GCT CCA CGT
CTT
CTC GCT CTC GTC TTT GTC CT
GCA TAG GCA CTG GTC TAG
CA
CAG ATG CTT CTG GAT TTA
TGG TAT T
TTG AAC TCC ATT CTT CAG
TGT AGC
TCG TGA TCT CTG AGG TTT
ATT TGT
ACA TCC TTT CTG CCA ACT GC
TGG TGG CAG AGT AAG CTA
GGA
AAA GCA ATG GGG AGT CCA G
GCT CAG GAG GAA TAG TGT
GGA
TGT TCA GGA TCT CCT CAT
TCT G
GGA CTG CTG CTT CTT TGG TC
TGC CAT GAC TGT TTG TCC TG
CAG CTT CTG CAC ACA TGA
CC
AAT GTG ACT CCG AAA AAC
CTG
GGA CAG AGA TGG CGG A
TGT ATG GAT GTA GAC GCA
TCT GT
AGG TCC CAG TCC GAG ATG
TA
CGT CTG GTA CTT GGT GTA
GGG
CTG GGA GGA GAT TGA ACC T
CCG GAC CTC AAC CAG GAC
TT

Table 2.1 – Primer sequences used for QPCR assays (Continued on next page)
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XRCC6
PARP1
ERCC1
XRCC2
RAD23B

AGA GTG AAG ATG AGT TGA
CAC CTT T
TCT TTG ATG TGG AAA GTA TGA
AGA A
GAA ATT TGT GAT ACC CCT CGA
C
GCC TGT CAG CTT TTT ACT GGA
T
CCC TGA CAG AGC AGT GGA GT

SFRS2

AAG ATT ATT ATA AGC AGC GGT
TAA GG
ACA CAT GTA AAG CAG TGT GTT
CC
CAG AAG GTG GCA GTG TAC
AGG
GGG CTG AGG ACC CAA AGT
CAA GAC CAG GGT GGT TGG
CTT TTG GAT CAA TTA CCA GTG
CT
TTG GCC AGT ATT GCA GAT TTT

SNRPB

CTG GAA GAG GGA CTC CAA TG

MED18

GAT ATA ATT CCC GGC TTC TCG

PAQR3
RNF41

ACA TGA GGA TTT GGG AAC
AGA
TGC CCT ATT TGC AGT GGA GT

QK1

AAC TTC TGC GGG ATC TTC AA

ERCC6
ERCC 8
TRADD
P53TG1
BAX alpha
PABC4
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CCA AGA GAT CTC GAT CAC
TGC T
GGC ATC TTC TGA AGG TCG
AT
GAT CGG AAT AAG GGC TTG G
CCT CAG AGT AGA CTC CTG
TAA GTT CA
GGT CAA CCA CAG CCT GAC
TT
GCA TCA CTT TCC TCA GAA
TCG
CAC ACT GTA TCT GTG AAC
ATC AGG
CAG CAT CTG CAG CAC GTC
TCA TTC TTC TCC CTG CGA GT
CAC TCC CGC CAC AAA GAT
AGC CAA ACC CTT TGC TTC TT
CAA TAC ACG CCC ACA GAA
AC
GGG CCA AGA TGA GTC TAG
GG
GTC AGG TAA GGC ACG GGA
TA
TCC GAG GTA GTT TAG TTG
TCC AG
CGT TGC AGA AAG CAT GTT
CA
TGT CTT TCC GTA CTC TGC
TAA TTT C

Figure 2.1- Heatmap from microarray suggesting differentially regulated genes in
0-time reduction mammoplasties. Green bar above denotes parous, while red
denotes nulliparous patients. Red symbols denote upregulation, while green
denotes downregulation.
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Figure 2.2 – QPCR data depicting various transcript levels isolated from 0-time
reduction mammoplasty specimens. Genes were chosen in order to confirm
signature produced by microarray. (* denotes statistical significance)
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Figure 2.3 - T=0 reduction
mammoplasty specimens were stained
for Clusterin IHC. Staining
predominately was found on the luminal
border of most ducts. There was also a
strong stromal signal found in most
patients. There was no appreciable
difference in intensities between
nulliparous and parous patients as
suggested at the level of transcript by the
microarray.
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Figure 2.4 – Photomicrographs showing T=0 reduction mammoplasty specimens
stained for NR4A2 (Nurr1) IHC. Both luminal and basal epithelial cells showed Nurr1
immunoreactivity. Nurr1 showed localization in bothe the nucleus and cytoplasm.
Stromal cells surrounding the ducts also showed some immunoreactivity. There was
no appreciable difference in Nurr1 intensity between parous and nulliparous patients.
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CHAPTER 3
DIFFERENTIAL SENSITIVITY TO IR-INDUCED APOPTOTIC DEATH IN
THE PAROUS BREAST

Introduction

We hypothesized that the parous mammary gland would have a greater sensitivity
to IR-induced apoptotic death. Our hypothesis was based on the fact that irradiated
parous mice show a persistent increase in sensitivity to apoptosis, as well as nuclear p53
accumulation when compared with age-matched nulliparous mice. This increased
sensitivity to death is also comparable to Estrogen and Progesterone- treated nulliparous
mice (Dunphy et. al 2008). Our first goal was to assay the sensitivity of the human
mammary gland to programmed cell death by first quantifying apoptosis by way of
TUNEL assay. Secondly, we wanted to correlate the molecular players conveying this
putative sensitivity by doing a high-throughput micro-array analysis, and QPCR to verify
microarray analysis. We reasoned that if the mammary gland is more sensitive to death
after a carcinogenic event then it would be unable to further progress and mature into a
cancer. Likewise, the genes we expected to see differentially regulated in response to IR,
should be those previously characterized to be differentially expressed in the parous
breast involved in cell death, and apoptosis.
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Apoptotic Pathways

Apoptosis and other forms of cell death are of great importance in describing
models of how cancer arises and progresses. Accordingly, it was also important in our
study to consider genes downstream from the previously mentioned DDR that are
involved in apoptosis. Apoptosis can arise from two separate courses: it can be induced
extrinsically through cell surface receptors or intrinsically from the mitochondria.
There are vast arrays of extrinsic cues that can induce programmed cell death.
Such cues include hormones, cytokines, toxins, or nitric oxide (Popov et al 2002, Brun et
al. 2003). Perhaps one of the most widely studied pathways involving programmed cell
death involves the second mitochondrial activator of caspases (SMACs) which are
released into the cytosol after an increase in the permeability of the mitochondrial
membrane. SMACs then bind the antagonists- inhibitors of apoptosis proteins (IAPs).
By binding the inhibitors, SMACs deactivate IAPs and the signal is transduced with the
proteolytic activation of caspases which eventually cause cleavage of genomic DNA. We
know that execution of apoptosis relies on the cleavage of Bcl-2 member Bid by caspase
8, which subsequently releases pro-apoptotic factors from the mitochondria, and drives
apoptosis (McDonnell et al. 1998).
There are two different mechnanisms by which apoptosis can be induced from
cell surfaces. One model involves the induction by the ligand tumor necrosis factor
(TNF). The second mechanism involves the Fas-Fas ligand-mediated model. Both the
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TNF and the fas-fas ligand-mediated models involve receptors of the TNF receptor
(TNFR) family which are specifically activated by extrinsic signals (Wajant et al 2002).
Although the pathways described are extremely abridged, the differential
regulation of these death pathways can allow the cells comprising the mammary gland to
show differential and flexible responses to extrinsic signals. Likewise, the genes
encoding the players involved in programmed cell death represent an indispensible class
of genes to consider when identifying mechanisms for a parity-induced sensitivity to IRstimulated death.

Role of p53 in Apoptosis

P53 is well supported in the literature as the affector that cues the apoptotic
response to DNA damage. Medina et. al demonstrated that mice primed with the sex
steroid hormones estrogen and progesterone (E+P), and then challenged with chemical
carcinogen methylnitrosourea (MNU) show nuclear accumulation of p53 (Medina et al
2002), an observation not seen in mice that were not primed with hormones (Medina et al
2000). Medina and Kittrell then demonstrated that p53 function was required for
hormone-mediated protection of mouse mammary tumorigenesis in response to DMBA
(7,12-Dimethyl-benz[a] Anthracene), and the absence of p53 abrogated a significant
portion of the protective effect exerted by short-term hormonal stimulation (Medina et al
2000, 2003). Taken together, these results suggest that p53 responsiveness is persistently
altered by hormonal stimulation of the virgin mouse mammary gland, and that p53
promotes cell cycle arrest and apoptosis in response to DNA damage.
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As mentioned previously, p53 is at a direct interface with the DDR as it is directly
activated by ATM. P53 is considered a tumor suppressor because of its ability to cause
transcription of many pro-apoptotic genes. p53 activates genes such as Bax, PIG3,
PUMA, Noxa, P53AIP. Interestingly, many of these same genes involved in cell-death
pathways have been shown to be upregulated in post-involuted rat mammary glands.
Several studies show this parity-induced fingerprint is characterized by an elevated
expression pro-apoptotic genes such as testosterone-repressed prostate message 2
(TRPM2), interleukin 1β-converting enzyme ICE), p53, p21, and c-myc. Bax was found
to be signficantly upregulated in the mammary gland of post-menopausal parous women
(Balogh et al 2007). Also, it was shown that upregulation of the pro-apoptotic gene bclXS was found to be upregulated in mammary glands of rats (Russo et al 2006).
These death-related pathways were vital in forming our hypothesis. If a
premalignant cell is induced to undergo apoptosis then it would never progress to form
advanced disease. Similarly the many pathways and innumerable genes comprising these
death pathways represent a reservoir of potential molecular candidates conveying the
long-term protection against breast cancer seen in early-parous women. By increasing the
transcription and production of these pro-death molecules through promoter alterations,
the parous breast could shift the axis to a mammary gland with a propensity towards
stress-induced death.
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Materials and Methods

Human Explants
Women undergoing elective reduction mammoplasties were asked to enroll in our
study and donate their excised tissue. Immediately following surgery, roughly 70 grams
of normal breast tissue was procured and dissected under sterile conditions. Small
portions (roughly 200mg), of stromal/epithelial tissue were grossly dissected from the
surrounding adipose tissue, placed on a small piece of surgical foam, and cultured in
phenol-free basal medium for 24 hours at 5% CO2 to allow for equilibration. The tissue
culture was then exposed to 5Gy of ionizing radiation while a duplicate organ culture was
left unirradiated as a control. The tissue was left in culture for the subsequent six hours to
allow for uninterrupted changes in gene expression. Finally, the replicate tissues were
fixed in formalin and flash frozen in liquid Nitrogen for immunohistochemical analysis
and RNA isolation, respectively. RNA was sent out for microarray analyses and
Quantitative PCR was performed to confirm our results.

Microarray
RNA was isolated from whole mammary tissue using Qiagen Minikit according
to manufacturer’s instructions. RNA was then eluted from the column with NFH20,
measured with a spectrophotometer, and sent to the Genomics Core University of North
Carolina, Chapel Hill under the care of Dr. Melissa Troester where it was reverse
transcribed and subject to microarray analysis.
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RT and QPCR
Total RNA from 50 mg of flash-frozen explants was isolated using TRIzol
reagent (Invitrogen) standard protocol. Libraries were generated with QSCRIPT (Quanta
Biosciences) using 100ng of total RNA as a template. Replicates were then diluted 1:10
for QPCR analysis. Ten independent RT reactions were pooled together to account for
variation in RT reaction, then serially diluted to generate a standard curve. Relative
amounts of target genes and normalizer genes were determined by plotting the critical
threshold (ct) values on their respective standard curve. To account for changes in a
particular gene, the normalized levels from the unirradiated explant cDNA (control) was
subtracted from the irradiated explant cDNA for each respective patient.
TUNEL
Four µm sections of mammary tissue were deparaffinized in xylene, rehydrated in
graded ethanol, and subjected to terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) of apoptotic DNA using the TACS XL Blue Label Kit (Trevigen). A
minimum of 2,000 mammary luminal epithelial cells were counted. Percent positive cells
were calculated by taking the ratio of positive cells over total cells counted for each
sample.Percent positive cells were calculated by taking the ratio of positive cells over
total cells counted for each sample.
Statistical Analysis
All statistical calculations were performed using GraphPad Prism Version 6.
Comparisons between groups were carried out using a Student’s pair-wise t-test
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Results

Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) of
apoptotic DNA was performed on paraffin embedded organ cultures. Nulliparous patients
had significantly more apoptotic epithelial cells (Mean = 2.683) than their parous cohorts
(Mean = .5809) 6 hours after irraditation. Parous patients also tended to cluster much
closer together (SD=.61%), whereas nulliparous patients had much more diffuse levels of
staining (SD=1.386). This data suggests that the nulliparous breast is more susceptible to
IR-induced apoptosis.
Our first micro-array analysis revealed a loose 200-gene signature which showed
differential transcriptional responses between parous and nulliparous women in response
to radiation. Breast tissue harvested from nulliparous women showed the most striking
changes with an increased expression of 80% of genes in response to radiation whereas
tissue from parous women showed no change or decreased expression of these same
genes. The other 20% of signature genes were strongly down-regulated in tissue from
nulliparous women in response to radiation, while they were up-regulated or remained
unchanged in parous tissue. Genes that regulate the ubiquitin/proteosome, cellular stress,
and Wnt pathways all were differentially regulated between parous and nulliparous
patient groups. Many other genes involved in vital cellular processes such as
transcription, translation, cytotaxis, and death were differentially regulated in response to
parity (Table 3.1).
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We chose to first focus our efforts on the death pathways suggested by our
microarray to be altered by parity. Table 3.1 suggests the pro-apoptotic Tumor Necrosis
Factor (TNF), pathway to be a viable candidate. Immediately, our signature shows three
key genes in this pathway. The downregulation of the TNF-α decoy receptor
TNFRSF10C, the downregulation of the TNF-α Receptor Associated Factor gene TRAF
5, and the upregulation of TRAF7 in parous mammary tissue are all important
observations. TNFRSF10C was shown to be downregulated in the parous breast in
response to (figure 3.1). QPCR was performed and TNFRSF10C was found to be
significantly upregulated in the nulliparous breast, while the converse downregulation
was found in the parous breast (P=.0031; Figure 3.9). QPCR data for TRAF 5 and TRAF
7 demonstrated no significant difference between parous and nulliparous glands (Figure
3.9). We tested TRAIP, TRIAD3, FADD, and TRADD (Figure 3.9) - several genes
involved in TNF death pathway to see if there was differential expression between parous
and nulliparous women. QPCR analysis showed that there was no significant difference
in expression levels between parous and nulliparous patients after irradiation.
We focused our efforts on confirming genes involved in growth and cell-signaling
which were suggested by our microarray data by QPCR analysis. The microarray
suggested several genes involved in the TGFβ signaling pathway. The heatmap from the
first microarray suggests that activin receptor type IIA (ARIIA) was downregulated in the
parous breast in response to IR (Figure 3.1). Although this didn’t seem to be a
statistically significant difference from the microarray, we aimed to confirm this trend by
QPCR. We were able to find a set of primers that produced a an acceptable standard
curve with a 1:4 cDNA dilution series. Many of our samples (diluted 1:10) showed little
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or no expression in any of our assays. cDNAs were remade and diluted 1:5 in order to
determine whether loading a more concentrated template would produce a functional
assay. This strategy did not prove to be effective as these same wells did not amplify. Our
first microarray also suggested the TGFβ family-related gene- smad nuclear interacting
protein 1 (SNIP1), however our explants seemed to have statistically insignificant
differences in this gene as determined by QPCR (Figure 3.11). Several other genes such
as transforming growth factor β receptor III (TβRIII) and NotchII did confirm with
statistical significance (Figure 3.8, 3.10). We wanted to see if our observed
downregulation of TβRIII message had a corresponding downregulation of TβRIII
protein. IHC was performed on paraffin embedded explants from 3 parous and 3
nulliparous patients. The myoepithelial cells of the mammary gland stained intensely for
TβRIII protein (Figure 3.6). Although two of the nulliparous patients followed our
expected trend in response to IR, one did not; the parous patients didn’t have any
appreciable change in intensity in response to IR. This preliminary data is important
because it suggests that the corresponding decrease in TβRIII protein might be a
significant finding. As of now we could only speculate with an n of 3 in each group.
Notch II was also suggested by the heatmap from our first microarray. According
to the array, there was a negligible change in transcription in response to IR. Conversely,
in nulliparous women there was a slight increase in Notch II transcript in response to IR.
We attempted to verify these results by QPCR, with 6 parous and 6 nulliparous patients
(Figure 3.10). We were able to repeat the trend that was seen in the microarray with
statistical significance (P=.05). Two of the nulliparous patients seemed to have extremely
low levels of this transcript, (ie amplification after 37 cycles of PCR). These patients
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were excluded from the analysis based on the appearance of the melt-curve.
Our first microarray suggested that the gene- splicing factor, arginine/serine-rich
2 (SFRS2) was downregulated in the parous explants in response to radiation. This
particular gene was of interest because splicing factors can have widespread effects on
multiple genes by differentially splicing mRNAs. We attempted to confirm SFRS2 by
QPCR and our results suggested that the differences between parous and nulliparous
patients at the transcript level were statistically insignificant.
Interestingly, several phase-two detoxifying enzymes were also found to be
upregulated in the parous breast in response to IR. QPCR Primers were designed for
NOXA, and glutathione peroxidase 2 (GPX2). We never developed a working assay for
NOXA because of the low abundance of the transcript in our standards as well as our
patient cDNAs. Basal levels of GPX2 on the other hand, were found to be significantly
upregulated in the parous breast prior to IR (Figure 3.13). Changes in GPX2 in response
to irradiation were found to be insignificant when comparing parous versus nulliparous
groups.
For our second microarray analysis, we sent out RNA from fifteen additional
patients. Many of the genes from our initial 200 gene signature were eliminated with a
larger number of patients included. Likewise we were left with a 21 gene signature that
confirmed for all 30 patients. This second heatmap (figure 3.2) represents a much more
stringent fingerprint with a reduced number of genes that are differentially regulated in
response to irradiation between parous and nulliparous patient sets.
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Discussion
TUNEL analysis revealed a surprising decrease in apoptotic death in parous
patients at our six hour timepoint. This result seemed counterintuitive given on what is
reported in the literature, with an increased incidence of apoptotic death in the mammary
gland of the parous rodents. Unlike the BALB/c animal model, the effects of parity on
human breast tissue appears to favor the increase DNA damage response over the
apoptotic response under our culture conditions. Furthermore it doesn’t seem as though
p53 plays as pivotal a role in our model as described in the mouse. In a previous project,
67 patients were stained for p53 by IHC. After extensive analysis and blinded scoring by
two pathologists, the immunoreactivity was found to be an insignificant difference
between parous and nulliparous groups. Lastly, the p53 target gene (p53TG1) levels were
measured by QPCR as it has been reported to be persistently downregulated in the postmenopausal parous mammary gland. P53TG1 did not show any significant change in
response to radiation (p=.7767). We can say fairly confidently that p53 isn’t differentially
regulated in our system, at the 6 hour timepoint. This does not exclude the possibility that
there might be differences in the length of time that p53 stays active between these
populations, but it does rule out a comparable change in p53 sensitivity as is observed in
the rodent model. This discrepancy between mouse and human models is an important
observation because is suggests there may be different mechanisms conveying this parityprotective effect between species.
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The pro-apoptotic BAX was chosen as a viable candidate conveying this
increased sensitivity to death seen in the nulliparous group for the reason that it was
reported to be expressed at 2.7 fold higher levels in the post-menopausal parous breast
(Russo et al 2008). Bax is also reported to be activated in response to IR directly through
Rac1 activation by p38 (Kim et al 2008). Although an increased expression of BAX
wasn’t seen in our nulliparous explants, there were significantly higher basal levels of
BAX transcript in unirradiated nulliparous explants. p38 transcript levels were also found
to be significantly upregulated in the parous breast in response to IR, which suggests that
the upregulation of this gene is driving a cytoprotective pathway. Interestingly, p38
MAPK has also been reported to regulate chromatin remodeling as well as DDB2
degradation for facilitating assembly of the molecular players comprising the NER
pathway (Zhao Q et al 2008). This data suggests that while the nulliparous breast may in
fact have a higher sensitivity to death, the epithelium comprising the parous breast has a
propensity of rescuing damaged cells via the DDR.
As mentioned earlier, NR4A2 expression has been shown to impart a pro-survival
phenotype of breast cancer cells by preventing anoikis (Ke et al 2004). Likewise, it was
shown that NR4A2 promotes the survival of neurons in the CNS. We showed that
NR4A2 was significantly upregulated in our parous T=0 reduction tissues both with our
microarray as well as QPCR. This could partially account for why we are seeing less
death in the parous tissue, as this upregulated pro-survival gene is saving the epithelium
from apoptosis.
We next shifted our focus further downstream of the DDR pathway to pathways
involved in cell death. We looked at many members of the TNF α superfamily and none
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were found to be significantly deregulated in response to IR in parous patients. One of the
genes we tested from this pathway did confirm with significance, however. TNFRSF10c
is well reported in the literature as a tumor suppressor gene. In fact, 8p21.3 is the locus
where this gene is found which happens to be the most frequently deleted locus in human
prostate cancer. Many reports have also shown promoter methylation upstream of
TNFRSF10c (Cheng et al 2008). This gene encodes a receptor that contains an
extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic
death domain. Ultimately, this receptor acts to dampen the pro-death signal conveyed by
the TNF molecule. This result would have a dominant-negative effect on the pathway, as
it was found to be significantly downregulated in the parous breast in response to IR. We
reasoned by way of our original hypothesis that if the parous breast is more sensitive to
IR induced death, then we would like to see a downregulation of this gene. If there were
less of this negative receptor being made, then the transduction of the pro-death pathway
should propagate more efficiently in the presence of TNF ligand.
There was another member an apoptotic pathway suggested by the literature to be
persistently upregulated in the post-menopausal parous mammary gland (Russo 2008).
Bcl2- associated factor x (BAX) was found to be significantly downregulated in the
parous breast prior to irradiation. The BAX transcript level showed a very small
upregulation to IR at our six hour post-IR timepoint. Conversely, in the nulliparous breast
there seemed to be an upregulation in this pro-apoptotic transcript 6 hours post-IR (figure
3.11). We next looked at the BAX levels in our 0-time reduction tissues. Contrary to what
we saw in our explants, it seemed as though the levels tended to be slightly upregulated
in the 0-time, noncultured tissues.
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Transforming growth factor-beta (TGF-β) is a multifunctional family of cytokines
that regulates tissue development as well as repair processes. Type III TGF-β receptor
(TβRIII) is downregulated in a wide range of human cancers, including breast cancer.
TβRIII is further supported in the literature as a bona fide tumor suppressor gene because
when TβRIII expression is restored in human breast cancer cells, breast tumor invasion,
angiogenesis, and metastasis are inhibited in vivo (Dong et. al 2007). The data obtained
from the microarray indicated that TβRIII is downregulated in nulliparous women in
response to radiation, whereas there was little to no change in the parous group (Figure

3.1). Our group was able to replicate the microarray data by choosing a myoepithelialspecific cytokeratin -CK14. Although the nulliparous values are more diffuse (SD= .95) a
number of the values decrease with radiation. The TβRIII levels in parous patients
clustered much closer together (SD = .27), suggesting a similarity within the
experimental group, and they don’t appear to be responsive to radiation (Figure 3.8).
We wanted to see if our observed downregulation of TβRIII message had a
corresponding downregulation of TβRIII protein. IHC was performed on paraffin
embedded explants from 3 parous and 3 nulliparous patients. The myoepithelial cells of
the mammary gland stained intensely for TβRIII protein (Figure 3.6). Although two of
the nulliparous patients followed our expected trend, one did not; the parous patients
didn’t have any appreciable change in intensity in response to IR. This preliminary data is
important because it suggests that the corresponding decrease in TβRIII protein might be
a real. As of now we could only speculate with an n of 3 in each group.
Several other important cytokines were also shown to be differentially regulated
in response to IR in the parous breast. For instance mitogen activated protein kinase 14
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MAPK14 (aka p38) was shown to be significantly upregulated in the parous breast in
response to IR. It becomes hard to speculate what role this increase of p38 message might
have physiologically because it might not correspond to an increase in protein. To rule
this out we stained our explants for p38 via IHC. This gene was unequivocally IRinducible, however there was very little staining seen at our 6 hour timepoint. Based on
evidence in the literature, we decided to stain our sections at half and one-hour post IR. A
majority of the specimens stained the most intense at our earlier, half-hour timepoint.
Although this experiment was useful to determine the timepoint at which to see robust
increase in p38 protein, it didn’t help to explain the significant parous upregulation in
transcript at 6 hours after irradiation. It’s also important to consider that p38 induction
can occur in a biphasic manner. It’s been reported that p38 activity indeed does have
biphasic properties with the first peak occurring at 1 hour, and the second peak occurring
between 6 and 8 hours (Van Wagoner 2000). We also tried spiking a p38 inhibitor onto
one parous and one nulliparous explant and staining those tissues for TUNEL to see if we
could rescue the observed sensitivity to apoptosis that we had seen earlier. The two
explants did have similar levels of TUNEL staining when treated with the inhibitor.
The gene GADD45A was chosen for QPCR analysis as it is activated in response
to IR. The GADD45A protein responds to IR and other environmental stresses by
activating the p38/JNK pathway via MTK1/MEKK4 kinase (Bulavin et al 2003).
Likewise, we reasoned that this gene could be used to explain the differential regulation
of p38 transcript between parous and nulliparous patients. The GADD45A activation of
the p38 pathway results in cell cycle arrest through activation of p53 (Bulavin et al 2003).
Most of our explants showed an upregulation in GADD45A transcript six hours after

37

irradiation. There didn’t seem to be a significant deregulation between parous and
nulliparous patient groups, however. Basal levels of this transcript were comparable of
between parous and nulliparous groups as well. It could very well be that we weren’t
examining the correct timepoint for this gene. It would be interesting to stain our explants
for GADD45a IHC at different timepoints to see when the maximal levels of this protein
occur after irradiation. We could also stain for players further downstream of GADD45a,
but upstream of p38. One such protein could be phosphorylated MEKK4 because this
would be more indicative of activity, suggesting a timepoint at which the pathway is
physiologically active.
The microarray produced from our explant culture had differential regulation of
several genes involved in the phase II detoxification system. The mammary tissues were
still somewhat metabolically active and they were likely producing reactive oxygen
species (ROS). ROS have long been characterized to be DNA damaging agents. Many of
the GPX Enzymes in the phase II detoxification process are involved in degradation of
these chemicals. GPX2 can also act to suppress COX-2 expression and PGE 2 production,
which explains its potential to inhibit migration and invasion of cultured cancer cells
(Brigelius-Flohé et al 2009). It was exciting to see this gene significantly upregulated in
the parous breast. This suggests that the parous breast is better equipped to degrade
DNA-damaging peroxides than the nulliparous breast. It is plausible that the early-parous
patient is less-likely to develop cancer because of the decreased likelihood of DNA
damage from peroxides. By upregulating the genes involved in the catabolism of these
chemicals, it further decreases the chance for a carcinogenic event.
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Figure 3.1- Heatmap generated from first microarray. Heatmap suggests
roughly 200 genes differentially regulated in response to IR. Green
represents an upregulation, and red represents a downregulation. Values
were generated by subtracting unirradiated explants, from irradiated.
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Death
AKT1S1
FADD
HuR
TRAF7
p53
ASNA1
PPP4C
PRKAG1
IER3
TNFRSF10C
TRAF5
PIM2
SAV1

Proliferation
Profilin
Csk
Spred
E2F4
IG5
Pbx1
RNF3
ZBTB20
Cyclin G2
PDGFa
Metallothionein
3
ErbB4

Stress
Pathway
FKBP52
SGSTM4
SGTA
TXNRD2
DUSP16
Cyp2B6
Cyp2A6
Cyp2A13
Cyp4x1
CypB561b1

Ubiquitin/Proteosome
RPN1
ADRM1
Trim25
NOB1P
UBE2M
UBE2Q
PSM013
SUMO3
IER3
DUB3

Wnt
Related
Profilin
Fli-1
IER3
Wnt5a
FzD10
LRRFIP

Translation
EIF4A1
EIF5A
EIF2S2
EIF4G1

Elk3

Table 3.1- Summary and coarse grouping of signature genes shown by microarray. Red
text indicates a downregulation in that particular gene in parous patients, green vice versa.
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Figure 3.2- Heatmap generated from second microarray. Heatmap suggests 21 genes
differentially regulated in response to IR. Many of the original 200 genes fell off the
original list when we increased the number of patients for analysis. Green represents
an upregulation, and red represents a downregulation. Values were generated by
subtracting unirradiated explants, from irradiated.
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Figure 3.3 – Photomicrographs from TUNEL assay and graphs from corresponding
data. Data suggests a decreased incidence of apoptosis in parous patients. Bar graph
and scatterplot were generated from the same values. P=.0023
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Figure 3.4 – p21 staining showing
immunoreactivity exclusively in the
nucleus of predominately luminal, but
some myoepithelial cells. 6 aged
matched parous and nulliparous women
were scored for percent positive cells
and intensities were noted. No
significant difference was seen between
parous and nulliparous patients.

Figure 3.5 – Photomicrographs from p38 (MAPK14) IHC stained, paraffin embedded
explants. P38 was unequivocally induced by IR. Most patients showed the greatest
amount of p38 immunoreactivity 60 minutes after irradiation. P38 stained
predominately in the nuclei of luminal epithelium. There was no appreciable
difference in p38 levels when comparing parous to nulliparous patients.
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Figure 3.6 – Photomicrographs from TβRIII(Betaglycan) stained paraffin embedded
explants. TβRIII stained most intensely in myoepithelium. Signal seemed to be
localized in both the cytoplasm as well as the cell membrane. Several epithelial cells
showed some nuclear localization although this is a membrane-bound receptor, as
seen in panel on lower right.
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Figure 3.7 – Photomicrographs showing IHC staining for ELAVL1 (Hurr) on paraffin
embedded explants. NR4A2 stained the most intensely in the epithelium of ducts.
There was signal seen in both the cytoplasm, as well as the nuclei. There was no
appreciable difference seen between parous and nulliparous groups
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Figure 3.8 – QPCR data from explants depicting basal levels as well as changes
in transcripts in response to irradiation. Genes were chosen in order to confirm
signature produced by microarray. (* denotes statistical significance)
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Figure 3.9 – QPCR data showing changes in expression of genes involved in the
TNF pathway after irradiation. TNFRSF10C was chosen in order to confirm that it
was differentially regulated in response to IR. ** denotes a significant change in
between parous and nulliparous sets.
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Figure 3.10 – QPCR data from explants depicting changes in expression
in response to irradiation. Genes were chosen in order to confirm signature
produced by microarray. (* denotes statistical significance)

49

Change in mSFRS2 Levels in Response to IR Normal to CK18

Change in mSFRS2 Expression

Change in mSNIP1 Expression

Change in mSNIP1 in Response to IR Normal to GAPDH

1.0
0.5
0.0
Nulliparous

Parous

-0.5
-1.0

mBAX Levels in Unirradiated Explants

Change in mBAX Expression

mBAX Levels in AU

0.5
0.0
Parous

Nulliparous

-0.5
-1.0
-1.5

Change in mBAX In Response to IR Normal to CK18

20
15
10

**
5
0
Nulliparous

1.0

Parous

15
10
5
0
-5

Nulliparous

Parous

-10

mBAX Levels Normalized to CK18

mBAX Levels in AU

2.0
1.5
1.0
0.5
0.0
Nulliparous

Parous

Figure 3.11 – QPCR data from explants depicting basal levels as well as
changes in transcripts in response to irradiation. Genes include the proapoptotic BAX. Lowermost scatterplot suggests slightly higher levels of BAX
in the parous 0-time reduction mammoplasties. The opposite trend was seen in
basal BAX levels in explants. (* denotes statistical significance)
50

Change in mMAPK14 Normal to CK18 in Response to IR
Change in mMAPK14 Expression

mMAPK14 Levels in Unirradiated Explants

mMAPK14 Levels in AU

1.5

1.0

0.5

0.0
Nulliparous

Parous

Change in m53TG1 Expression

0.8
0.6
0.4
0.2
0.0
Nulliparous

0.5
0.0
-0.5

Nulliparous

Parous

-1.0
-1.5

Figure 3.12 – QPCR data generated
from explants in response to IR
MAPK14 (p38) transcript levels.
MAPK14 was chosen as it was
suggested to be differentially
regulated by our microarray. Minor
increases of p53TG1 transcript
suggests that the p53 is not the
major stress pathway at 6 hours
post-IR in our system. (* denotes
statistical significance
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Figure 3.13 – QPCR data showing increased levels of phase-2 detoxifying
enzyme GPX2 in the parous explants. There was no different change seen in
expression between parous and nulliparous patients after irradiation. GPX2
was suggested to be differentially regulated by our microarray. (* denotes
statistical significance.
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Figure 3.14 – QPCR data showing expression levels of GADD45A.
GADD45A was chosen as it is induced by IR and is at interface with MAPK14
signaling pathway. No appreciable difference in expression was seen between
parous and nulliparous patients.
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Figure 3.15 – QPCR data showing slightly increased levels of the p53 responsive
genes- P53AIP and MDM2 in irradiated parous explants. Neither of these genes
were found to be statistically significant.
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CHAPTER 4
INCREASE IN NUCLEOTIDE EXCISION REPAIR (NER) PATHWAY IN
RESPONSE TO IONIZING RADIATION IN THE PAROUS BREAST

Introduction
DNA Damage Repair (DDR) Pathway

The DNA Damage Response (DDR) is the furthest upstream system to consider in
response to DNA breaks. Having a firm understanding on how cells comprising the
mammary gland senses and responds to DNA damage is instrumental to identifying
specific molecular players that convey a parity-induced protective effect. As mentioned
previously, IR is characterized by its ability to cause double-stranded DNA breaks
(DSBs). There are two major types of DSB repair pathways – homologous recombination
repair (HRR) and nonhomologous end-joining (NHEJ). The framework of what we know
about how the cell senses and reacts to a compromised genome has come from primarily
from yeast studies. One of the first and best characterized pathways involving the DDR is
a pathway involving the serine/threonine kinase Ataxia telangiectasia mutated (ATM).
This classic pathway was first characterized in response to IR. ATM was shown to
phosphorylate and activate the tumor suppressor p53 which then can cause apoptosis.
ATM is also the major kinase that phosphorylates H2AX in response to double strand
breaks (Burma et al. 2001). BRCA2 is reported to associate with the RAD51 protein, and
this complex acts to load RPA proteins which signal to a variety of other downstream
molecules and the repair process begins. We also know that P53 is required to activate
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p21 causing G2 arrest following DNA damage with IR (Bunz et al. 1998). The ATM
pathway is extremely important because it serves as the interface where the cell fate is
decided between apoptosis and senescence.
Over the past ten years, research has proven the DNA damage response to be
more diverse and complicated than the activation of the proverbial ATM pathway in
response to double-strand breaks. To date,
five independent molecular complexes have
been shown to sense and signal in response
to various types of DNA damage. (Harper,
Elledge 2007). For example, further
upstream we know the three-member
Mre11-Rad50-Nbs1 (MRN) complex
directly detects DSB’s and recruits ATM to
the compromised site of DNA (Lee et al.
2005). This level of complexity indicates

the broad array of molecular players that

Figure 4.1a – Schematic showing
how eukaryotic cells sense and
respond to DSBs – the main type of
DNA damage caused by IR.
Oncogene (2003) 22, 5792–5812

could be differentially regulated and
activated in response to parity.
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NER Pathways
The nucleotide excision repair (NER) pathway is reported to be the most versatile
DDR pathway and is responsible for removing a wide spectrum of bulky DNA lesions
that distort the helical shape of DNA.
Ultraviolet irradiation, antitumor drugs
(cis-platin), and some toxins found in
food are some of the environmental
agents that can cause bulky lesions in
DNA which can inhibit efficient
replication and/or transcription
(Maddukuri et al 2007). There are two
distinct pathways comprising in the
NER pathway: global genome repair
(GGR) and transcription-coupled
repair (TCR).
As the name implies, GGR is
responsible for sensing DNA damage
throughout the entire genome via the

Figure 4.1b – Schematic showing GGNER and TNER pathways in response to
DNA damage from bulky lesions. Genes
and Dev. (2002) 13:768–785.

XPC-hHR23B complex. Global
Genome GG-NER is reliant upon the hHR23B sensing the bulky lesion, and recruiting
other molecular players that act to repair the damaged strand. hHR23B then recruits and
complexes with XPC (Sugasawa et al 1996). This complex then further distorts the helix,
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recruits TFIIH, and the repair process commences (Evans et al 1997) This XPC complex
then acts as the initiator of GGR (Sugasawa et al 1998).
Transcription-coupled nucleotide excision repair (TC-NER) is a specialized
pathway identified in the mid-1980’s by the Hanawalt lab. The TCR pathway is
important for recognizing and removing lesions from the template strand actively being
transcribed by RNA pol II. The stalled polymerase acts to signal further downstream to
recruit and activate the assembly of other TC-NER proteins. TC-NER is of key
importance to sense and bypass stalled transcription complexes in order to recover
synthesis of the original mRNA molecule. Repair of any damage on the template strand
relies upon active transcription. Chromatin relaxation is one of the first requisites of TCNER which serves to allow the NER machinery access to the damaged strand. NER
genes are thought to be responsible for single strand break repair of large DNA adducts.
CSB (also known as ERCC6) is a SWI2/SNF2 ATP dependent chromatin
remodeling protein (Troelestra et al 1992, 1996). ERCC6 directs the excision nuclease to
RNA polymerase stalled at a lesion in the transcribed strand and has shown to be
upregulated in the parous breast of post-menopausal women (Russo et al 2007). ERCC8
has been shown to be upregulated in the parous breast (Russo et al 2008). ERCC8
encodes a WD domain-containing protein called CSA, and has been shown to interact
with CSB (ERCC6) as well as RNAPolIIA. CSA is also shown to be the vital component
of an E3 ubiquitin ligase complex (Groisman et al 2006). These two factors appear to
work together in early transcription-coupled nucleotide excision repair, and it was also
shown that CSB is one of the substrates used by the E3 ligase formed by CSA, which gets
targeted for proteosomal degradation following activation of the TC-NER pathway
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(Groisman 2006). CSB also interacts with Cullin4A are important for transcription
coupled-nucleotide excision in particular. ERCC1 physically interacts with the XPF
endonuclease (ERCC4) and this interaction catalyzes the 5’ incision of the damaged
DNA strand (Choi et al 2005). Excision Repair Cross-Complementing Rodent Repair
Group 2 (ERCC2) was shown to be persistently upregulated in the parous mammary
gland (Russo et al 2007). ERCC2 is reported to be a vital component of nucleotideexcision repair (NER) (Troelstra et. al 1992).
Ribosomal Protein S3 (RPS3) functions as a DNA endonuclease intimately
involved in the NER pathway. RPS3 has also been shown to be persistently upregulated
in the parous mammary gland (Russo et al 2007). The RAD51-like 1 has single stranded
DNA binding and ATPase capacity, is involved in the homologous recombination repair
has also been shown to be persistently upregulated in response to parity (Baybrooke et al
2000, Russo et al 2007). These aforementioned genes represent components in the first
system to be called into play in response to a double strand break, and they represent a
potential reservoir to which we may discover several potential players conveying the
parity protective effect.
Small nucleotide polymorphisms in the NER pathway genes may modify breast
cancer risk. Polymorphisms in ERCC2 have been suggested to modify the risk for breast
cancer after low level radiation exposure in radiation technologists (Rajaraman 2008). A
separate study of breast cancer cases versus controls in New York found that even in the
absence of radiation, polymorphisms in ERCC2 are associated with a 25% increase in the
odds ratio which may be further compounded by the presence of other polymorphisms in
the NER pathway (Crew 2007). Lastly, polymorphisms in the NER pathways genes have
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been suggested to modify the relationship between smoking and breast cancer in African
American women (Mechanic 2006). Thus, there is plenty of indication that changes in the
pathway could play a potential role in protecting against breast cancer
We know that the DDR is vital to consider as several players in the DDR have
previously been shown to be differentially regulated in the parous mammary gland. Many
members comprising the nucleotide excision repair (NER) pathway are reported to be
differentially regulated in the parous breast. Although this pathway is classically
activated by UV radiation causing bulky bases such as thymidine -dimers, it is an
important consideration of the DDR that is reported to be affected by parity.

Materials and Methods

Human Explants
Women undergoing elective reduction mammoplasties were asked to enroll in our
study and donate their excised tissue. Immediately following surgery, roughly 70 grams
of normal breast tissue was procured and dissected under sterile conditions. Small
portions (roughly 200mg), of stromal/epithelial tissue were grossly dissected from the
surrounding adipose tissue, placed on a small piece of surgical foam, and cultured in
phenol-free basal medium for 24 hours at 5% CO2 to allow for equilibration. The tissue
culture was then exposed to 5Gy of ionizing radiation while a duplicate organ culture was
left unirradiated as a control. The tissue was left in culture for the subsequent six hours to
allow for uninterrupted changes in gene expression. Finally, the replicate tissues were
fixed in formalin and flash frozen in liquid Nitrogen for immunohistochemical analysis
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and RNA isolation, respectively. RNA was sent out for microarray analyses and
Quantitative PCR was performed to confirm our results.
Microarray
RNA was isolated from whole mammary tissue using Qiagen Minikit according
to manufacturer’s instructions. RNA was then eluted from the column with NFH20,
measured with a Spectrophotometer, and sent to the Genomics Core University of North
Carolina, Chapel Hill under the care of Dr. Melissa Troester where it was reverse
transcribed and subject to microarray analysis.
RT and QPCR
Total RNA from 50 mg of flash-frozen explants was isolated using TRIzol
reagent (Invitrogen) standard protocol. Libraries were generated with QSCRIPT (Quanta
Biosciences) using 100ng of total RNA as a template. Replicates were then diluted 1:10
for QPCR analysis. Ten independent RT reactions were pooled together to account for
variation in RT reaction, then serially diluted to generate a standard curve. Relative
amounts of target genes and normalizer genes were determined by plotting the critical
threshold (ct) values on their respective standard curve. To account for changes in a
particular gene, the normalized levels from the unirradiated explant cDNA (control) was
subtracted from the irradiated explant cDNA for each respective patient.

Results

Given there was less death seen in the parous breast, we decided to explore
transcriptional responses of genes involved in the DDR, upstream of apoptosis. If there

61

was truly less death seen in the parous breast, we should see a heightened response in the
systems involved in repairing compromised DNA. Of the many genes tested, only genes
involved in the NER pathway showed a statistically increased response after irradiation in
the parous breast. In response to IR- ERCC1, ERCC2, ERCC6, and ERCC8 were
significantly upregulated in the parous breast and downregulated or showed no change in
the nulliparous breast. Other players such as ERCC4, and ERCC5 didn’t change
significantly in response to IR between parous and nulliparous patients. Genes involved
in the Base Excision Repair (BER) pathway all showed comparable responses between
parous and nulliparous patient groups. Genes such as RPS3, XRCC2, XRCC6, and
PARP1 all showed insignificant differences in expression when comparing parous to
nulliparous tissues.

Discussion

The data produced by our TUNEL assay argued against our original hypothesis. It
is interesting to note that Balb/c mice which have been frequently used to show parity
induced sensitivity to death are mutant in some of their DNA repair capabilities.
Although the genetic basis for this observation has yet to be elucidated, it was reported
that the Balb/c strain of mice is deficient in DSB rejoining, which seems to be specific to
the NHEJ pathway (Okayasu et al 2000). This deficiency in DDR could be the basis for
why there was increased apoptosis in the mouse model. Opposite of what was reported in
the mouse, the parous breast is actually less susceptible to IR induced apoptosis, while
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the nulliparous breast showed an abrogated apoptotic response. Although this decreased
sensitivity could be seen as a risk factor, there are various other mechanisms upstream of
cell-death such as a heightened DDR that could be allowing the parous mammary gland
to deal with genotoxic stress more efficiently. In order to test this hypothesis, we decided
to test several genes involved in the DDR, reported to be differentially regulated in
response to parity. We chose several genes involved in the NER such as ERCC1,
ERCC2, ERCC6, and ERCC8. We also chose several genes involved in the BER pathway
RPS3, RAD23, RAD51-Like1, XRCC2 and XRCC6, and PARP1. Interestingly, many of
the NER pathway genes showed significantly different responses between the parous and
nulliparous breast, all of the BER genes showed insignificant differences in response to
IR. This suggests that whatever mechanism might be conveying this decreased sensitivity
to IR induced death may very well be specific to the NER pathway. According to the
literature, double stranded breaks are thought to activate the non-homologous end joining
(NHEJ) pathway. The NHEJ pathway is comprised of numerous enzymes such as DNAPK, Ku70 and Ku80, which sense and form a complex at the site of the DSB, aligning
short homologies in overhand regions, and the Ligase IV/XRCC4 complex that seals the
break (Grawunder et al 1997). It was interesting that so many genes involved in the NER
pathway were differentially regulated in response to IR. As noted before, although an
abrogated NER pathway has been reported multiple times in the literature to coincide
with a reduced risk of breast cancer, IR is not the classically described perturbation used
to activate this system. It is possible that IR could induce some single-stranded breaks in
our system. Perhaps the ability of IR to cause the conversion of reactive oxygen species
from water could be used to explain the induction of the NER pathways.
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In general, the parous mammary gland seemed to have greater basal expression
levels of ERCC1, and ERCC8 prior to irradiation. None of the differences seen in basal
expression levels for the NER genes were significant, however the increased basal levels
of transcript are certainly an important observation. ERCC1 for instance, is the excision
nuclease that is vital for DNA cross-link repair. Increasing basal levels of these genes
could be a mechanism by which the parous mammary gland abrogates the NER pathway.
Clusterin also deserves mention in this model, as it is well-documented that is the
protein is activated by IR after double-stranded breaks. An exciting immunoprecipitation
experiment determined that after short-term IR exposure, CLU coprecipitates with Ku70
and Ku80 in MCF7 breast cancer cells, and signals for cell-death (Yang et al 1999). It
would be interesting to see if the sensitivity that was seen in the nulliparous breast could
be due to an increase in this association.
The results presented inspire potential for many future experiments. It would be
fascinating to further narrow these observations down to an enriched epithelial cell-type.
Ideally, some of these experiments could involve isolating human mammary epithelial
cells (HMECs) from our reduction mammoplasty tissues. These HMECs could serve as
the bridge to a more targeted approach to identifying the protective factors conveyed at
the level of the epithelium. The most promising route in these future directions involves
the phenomenon seen in the NER genes and the DDR. One of the first assays we would
like to do is an alkaline comet assay. Given that we saw an increased DDR in the parous
breast, we would expect to see less cleaved DNA and a smaller “tail”, in the HMECs
isolated from parous women. Likewise, if there truly is a propensity for the nulliparous
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breast towards apoptosis as opposed to repairing the DNA, we would hope to see more
damaged DNA and a larger “tail,” six hours following irradiation.
It would be interesting to see if the parity-dependent trends seen the NER
pathway from our explants system could be repeated in an enriched HMEC culture.
Initially, it would be necessary to choose the same 5 Gy dose and 6 hour timepoint. It
would be fascinating to elaborate with earlier timepoints as perhaps one DDR pathway
(NHEJ) is favored at an earlier timepoint, and whether or not these nuances in IR
response are parity-dependent phenomenon.
CLU would be a fascinating protein to study in this HMEC system. We would
irradiate them, isolate nuclear protein lysate, immunoprecipitate CLU complexes, run and
probe the precipitates on a western blot. We would ultimately like to see if more CLUKu70 complexes were found in the nulliparous HMECs. A stronger band could be a great
way to propose a sensitized death in the nulliparous patients, as the CLU-Ku70
association should signal downstream to induce apoptosis or at the very least, G1 cellcycle arrest.
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Figure 4.2- QPCR data showing increased expression levels of genes comprising
the NER pathway in response to IR in parous explants. ERCC genes were chosen
because ERCC2, ERCC6, and ERCC 8 were reported by Russo to be upregulated
in the parous breast of post-menopausal women. (*denotes statistical significance)
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Figure 4.3 – QPCR data depicting changes in expression of more genes involved in
the nucleotide excision repair NER pathway after irradiation. * denotes statistical
significance
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Figure 4.4 – QPCR data depicting no significant change in genes involved with
BER pathway between parous and nulliparous explants. BER genes were
chosen because they were previously reported to be significantly upregulated in
the parous breast by Russo.
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Figure 4.5 – QPCR data depicting more genes involved in the BER pathway. No
significant difference was seen between parous and nulliparous explants. The
above genes were also reported by Russo to be persistently upregulated in the
parous breast.
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CHAPTER 5
EXPERIMENTAL DESIGNS AND APPLICATIONS TO HUMAN TISSUE BANK
Introduction
Human Reduction Bank and Inherent Caveats

To date, 212 breast reduction specimens (both flash-frozen and paraffin
embedded) have been collected; 180 of these specimens have corresponding interview
information. Likewise, this bank represents an amazing resource with which to study the
various factors and genes that determine susceptibility to breast cancer. A majority of this
project was aimed at designing experiments and analyses around inherent caveats
conveyed by sampling flaws in our patient populations. Additionally, as breast tissue is
highly variable in composition between patients of different breast densities, age groups,
reproductive history, etc., it creates further difficulties in deriving meaningful data from
our bank. This chapter will address the various ways in which these confounders and
caveats were considered in both experimental design and analyses of various
experiments.
The greatest amount of time on this project was spent on getting reliable QPCR
data from our patient groups. A definite source of error accounting for this is as follows:
our transcriptomic studies were done with mRNA derived from whole breast tissue.
Whole breast tissue is highly heterogeneous, and this heterogeneity differs greatly from
patient to patient. Similarly, whole mRNA isolations taken from this heterogeneous tissue
are likely to be differentially representative of epithelial, stromal, adipose, and to a lesser
extent, immune cells. Immediately, this heterogeneity should account for unwanted
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variation within and between parous and nulliparous groups. Several groups, namely
Russo got around this problem by using laser-capture micro dissection to preferentially
isolate mammary epithelium from ducts, lobules, and terminal end buds (Balogh et. al
2006).
Another source of error comes from the fact that reduction tissue could very well
be differentially representative of the breast itself based on where the surgeon
preferentially dissected, and arbitrarily portioned the tissue for the study. Some portions
could contain different amounts of ducts, terminal end buds, lobules, etc. For example, if
the surgeon takes breast tissue more deep, nearer the pectoralus, we would expect the
tissue to be enriched for secretory cells found in lobules. Conversely, if the tissue was
excised more superficially, we would expect significantly ductal structures. Likewise, we
should expect a large variation in the cell types comprising these various structures as
each aforementioned part of the mammary gland serves distinct physiological roles. A
large part of this drawback comes from the different areas of the breast that were excised
and selected based on different surgeons with different techniques, varying from case to
case. This different composition based on actual cell-type should also account for
unwanted variation in our transcriptomic studies as does the different percent
composition by (density of the) tissue. Both of these caveats should and have affected the
extent to which we can evaluate and score protein levels in the specimens by IHC.
There was a large age inequity between the parous and nulliparous patient groups.
Nulliparous patients were 20 years younger on average than the parous patients. This
greatly limited the number of patients we could use for comparison in experimental
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analysis. A well designed experiment should test the same age groups of women, and
examine parity as the sole variable affecting breast cancer risk.
The CDC estimates a 24 percent obesity-rate of women living in the state of
Massachusetts. We should also expect that larger women have larger breasts on average,
and would be more frequently getting breast reductions as compared to the rest of the
population. Our database suggests this trend with 36 percent of our patients being obese,
as determined by their body mass indices (BMIs). This 15 percent enrichment for obesity
represents another inherent caveat in our sampling. This large discrepancy could greatly
affect our ability to generalize any of our findings to the general public, as our tissue
bank represents an extraordinary population. While many of our findings could be
suggestive of certain protective dispositions, obesity has long been known as a potent risk
factor for developing multiple different types of cancer. With this in mind we need to be
cautious about our choice of words as the project while close, isn’t representative of the,
“normal” breast.
Lastly, it should be mentioned that we were unable to determine where in their
menstrual cycle the patients were at the time of surgery. Although this wasn’t built into
our panel of interview information, including this question could have at least provided
us a rough estimate as to where in their cycle each patient is. This information could
possibly be more important than knowing the age of the patient as the mammary gland is
highly estrogen (ER) and progesterone (PR) positive. Likewise, the mammary gland is by
definition a “target tissue” for the hormones estrogen and progesterone. When bound to
its respective receptor(s), these hormones are potent transcription factors that cause the
transcription of many genes downstream of many different ER- or PR- specific
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promoters. As the menstrual cycle is defined by monthly oscillations in circulating
estrogen and progesterone levels, these variations should be significant confounders,
particularly in a transcriptomic study. An example of this could be with the gene CLU,
which was suggested by our microarray of 0-time tissues. Estradiol treatment of
endometrial cells was reported to induce expression of CLU (Ahn et al 2008). Although
designing our experiments around this factor would be severely limiting to the number
viable patients could be included into our study, it could at the very least be used as an
argument to discount any particular women that don’t fit a certain paradigm. As
mentioned with CLU, preemptively including this confounder with our analysis could
either confirm or refute this particular finding as it could have either made CLU (and
many others) statistically significant, or it could have left it (an many others) completely
unmentioned in our microarray. As mentioned previously, inhibin and activin α, βA, and
βB subunits (both at the message and protein level) were reported to be present in normal
breast tissue regardless of the time of the patient’s menstrual cycle or menopause (Reis
et al 2004). The estrous-independent expression of these genes suggests that these genes
have an amazing potential and demand future exploration in our tissues, as they shouldn’t
be affected by the circulating levels of estrogen and progesterone (E&P).

Quantitative PCR and the Use of Suitable Normalizers

One of the best ways to derive meaningful transcriptomic data, regardless of the
aforementioned sampling flaws associated with our bank is to use a normalizer that is
both relevant and similar in abundance to the gene of interest. One of the first genes to be
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used as a normalizer at the beginning of this project was GAPDH. This gene was chosen
as it was classically described as a reliable and relatively stable metabolic gene with little
variation associated between patients, or experimental groups. Recent literature now
suggests that this gene is in fact significantly and persistently upregulated in the parous
breast (Russo et al 2006). Likewise, as this gene is high in abundance, many of the genes
we chose to explore were particularly low in abundance and would amplify 10-15 cycles
downfield. 18srRNA was another gene initially used to normalize for our genes of
interest. This gene was also widely used by Russo as a normalizer in order to verify their
microarray data. Our findings show that this RNA is remarkably abundant and amplified
well out of the acceptable range for our genes of interest. Genes that seemed to show
consistent, repeatable data were the cytokeratins, namely CK14, and CK18. As shown in
figure 5.2, the overlap of a 1:3 CK18 standard curve is within the same range of most of
our genes of interest, as seen with ERCC2. This overlap seems important as experiments
designed with the appropriate normalizers produced repeatable results that seemed to
align better with our microarray. Assays testing the bearing of normalizer on
experimental outcome are demonstrated in figure 5.3. Not only can the normalizer
completely change the outcome of the experiment, but it can also abrogate the findings of
the assay. This factor is demonstrated by the scales seen on the y axes. The GAPDH
assay suggests that the changes in TGFBetaII transcript are 2 fold larger in magnitude
than the assays using 18SrRNA and CK18 as normalizers.
Towards the end of the project, many of the genes that we chose to analyze were
predominately suggested by the literature, and not by the heatmaps generated by our
microarray. Oddly enough, we were able to generate much more significant data by
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looking at genes and markers suggested by journals than we were ever close to by trying
to verify with microarray. For our particular tissue collection, and our particular system
of isolating RNA, microarray, although very convenient and time-saving, may not be an
appropriate assay based on the heterogeneity of our tissue. Likewise, with microarray
analysis, RNA isolated from breast cancer cell lines were spiked onto a chip and used as
normalizers to show whether or not a gene was high or low in expression. In addition, we
had our microarray data analyzed independently via two different methods, by two
different scientists, and this produced two radically different heat maps with very little
overlap. Although by using two different microarray platforms allows for a stringent test
that aligns with the status quo protocol published in the literature, it doesn’t correct for
any the aforementioned variations seen in our tissue composition. Prospectively if we
were to microdissect any of our flash frozen tissue to enrich for epithelium, microarray
might be a much more suitable assay. As was learned by doing this project, reproducible
transcriptomic data was acquired by performing QPCR analysis.

Immunohistochemistry
The goal from the beginning of this project was to section and stain our paraffin
embedded tissues with the hopes of showing differential percentages and intensities of
various proteins in parous versus nulliparous women. Although we optimized numerous,
highly-specific and reproducible staining protocols for many different antibodies, none of
these studies showed differential staining in response to parity. One of our most extensive
experiments was done by staining 67 patients for p53, and the intensity of both the
luminal and myoepithelial cells were blindly scored independently by two pathologists
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(data not shown). The results were insignificant even with this large number of patients
chosen for analysis. Although many of the subsequent IHC’s were done with a much
smaller number of patients, there were no appreciable differences in any of the tissues
based on parity, age, etc. In addition to this, IHC tends to get very expensive, very
quickly.
Although, IHC didn’t prove useful to show differential regulation of specific
genes at the level of protein, IHC did answer a wealth of questions about certain
characteristics of the respective gene of interest. For instance, when we stained for
Betaglycan there was no appreciable difference in either staining or intensity of this
protein between nulliparous and parous populations. After staining these tissues, it
became apparent that a majority of its expression was localized to myoepithelial/basal
epithelial cells. After discovering this attribute, we then used the myoepithelial/basal cell
marker CK14 as a normalizer in our QPCR assay, and we were able to reproduce the
trend originally seen in our microarray. Another important attribute this technique
seemed to be useful for was timepoints of expression. For example, when we stained for
p38 in our explants, it showed that much of the expression at the level of the protein took
place at the very early time point of a half-hour. This is extremely important information
as it verifies whether or not we are looking at the correct time to see differences in
expression of particular genes. Lastly, as we used IR to perturb our explants, IHC was
extremely indicative of whether or not that specific gene was responsive to radiation.
Again, it should be noted that this cause and effect relationship is dependent upon
whether or not we fixed the explants at a relevant timepoint, but it did prove useful for
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the most part to see whether or not a particular gene was upregulated or not in response to
irradiation.
In summary, IHC was important to this project to show whether or not as well as
which specific tissues or cell types the particular gene is expressed. This technique also
suggested whether or not the specific gene was IR-responsive, and at which time after
irradiation we could expect to see induction of a certain gene. Conversely, IHC proved
ineffective in our system to show differential expression levels of any genes that we’ve
tested to date, at least when comparing parous versus nulliparous patient groups. In the
future this technique may prove useful to flag cells that are existent in very small
numbers. Immune cells have been reported to be existent in the mammary gland. Another
potential use for IHC could involve another marker for death such as the M30. Having a
highly specific stain for a ligand associated with apoptosis could prove to be a lesssubjective means for quantifying apoptosis.

Paraffin Sections and TUNEL Assay

One final note regarding the TUNEL study involves the integrity of the tissues
produced at the end of this procedure. One of the prevailing problems of this assay was
that many of the ductal structures produced from this procedure were completely
collapsed. This phenomenon seemed to be a patient-specific. Some patients had perfectly
intact ducts, while others compromised structures with epithelial cells spilling into the
lumen. Interestingly, cells that were part of structurally compromised/collapsed ducts
seemed to have significantly more signal than cells composing an intact duct. Although
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all the tissues were procured, cultured, fixed, embedded, sectioned, and stained the same,
some patients’ ducts seemed to have more structural integrity than others.
This collapsing of the ducts could come from culturing for 24 hours, the fixation
processes, and/or the actual TUNEL assay itself. Although supplementing a piece of
mammary tissue with necessary nutrients enables us to keep it alive, there still was a
great deal of stress put on our explants. Firstly, oxygen can only diffuse roughly 10
microns through tissue. Our explants were pieces of whole breast tissue about 2 mm
thick, so there could have been a fair amount of hypoxia occurring. This hypoxia could
account for some of the compromised architecture. This observation could have also been
attributed to the lack of suitable nutrients necessary to maintain a stable gland. Our
phenol-free medium was very basic and didn’t contain any serum or additional growth
factors. This basic lack of nutrients could have also caused the collapse of many of these
structures.
The fixation process could also be blamed for the structural deterioration of our
tissue. Our tissue was fixed for 24 hours in NBF at 4C, and transferred to 70% ethanol at
4C where it would sit indefinitely, (anywhere between a week to a several months) until
they were processed, and embedded in paraffin. The time the tissues spent in ethanol
varied greatly from patient to patient, which could account for some of variation.
Intuitively, we would expect the tissues that spent the longest period of time in ethanol, to
have the greatest deterioration.
The chemistry involved in the TUNEL assay requires that you permeabilize the
tissue so the enzymes can properly perfuse the nucleus and access the DNA. The optimal
amount permeabilization was achieved by dissolving the proteinase K 1:20 in a 10mM
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Tris solution with a pH of 8.0. The proteinase K was left to digest the tissue at 37C for 15
minutes, and this seemed to be the least amount of time required so that all tissues would
be adequately permeabilized. During the optimization it became clear that certain women
required less permeabilization, while some required more. This phenomenon did not
seem to depend upon the parity status of the donor. This phenomenon made this assay
extremely difficult to standardize. The tissues that inherently needed less
permeabilization would get often get over-permeabilized. This is a caveat that could
easily account for the destruction of the ducts. With all of the incubation and wash steps
involved in this assay, this was likely the most prominent contributor to the destruction of
the ductal architecture. We can say this with some degree of confidence based on the fact
that similar sections were cut from the same paraffin embedded blocks and either stained
for IHC or even simple H&E stains. Looking at these slides retrospectively, it seems as
though while some of the ducts are compromised, none of them seem to be near the
degree or severity as some of the slides produce by our TUNEL assay.
Over 100 sections were cut and stained for TUNEL, and of those we could only
count 28 based on the fact that they still had intact ducts. Although we might have been
overly stringent by discounting so many slides, we felt as though we were justified as
there did such a striking increase in the number of positive cells comprise collapsed
ducts. If this were not taken into account, the data would have surely been radically
different as well as unreliable.
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Figure 5.1 – Amplification plots from standard curves showing the difference in
abundance from commonly used normalize genes (leftmost) as well as some
genes of interest (rightmost) explored in this project.
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Figure 5.2 – Amplification from standard curves showing large area of overlap
between the normalizer (CK18) and gene of interest (ERCC1), emphasizing the
importance of the normlizer having a similar abundance to the gene of interest.
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